Barclays
BIOL

Barclays’s Biolase, Inc. BIOL Stock Holding History

Barclays’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$2K – 5749
2021
Q4 		$2K Buy
+2
New +$2.52K ﹤0.01% 4057
2021
Q3 		– Hold
0
– – – 5079
2021
Q2 		– Hold
0
– – – 5125
2021
Q1 		– Hold
0
– – – 4619
2020
Q4 		– Hold
0
– – – 5209
2020
Q3 		– Hold
0
– – – 5681
2020
Q2 		– Hold
0
– – – 6388
2014
Q4 		– Hold
0
– -$3K – 7671
2014
Q3 		– Hold
0
– – – 7343
2014
Q2 		– Hold
0
– – – 7215
2014
Q1 		– Hold
0
– – – 7346
2013
Q4 		– Hold
0
– – – 7459
2013
Q3 		– Hold
0
– – – 7319
2013
Q2 		– Hold
0
– – – 7266

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
ZF
Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

Barclays's BIOL Position: Q1 2022 in Review

Barclays sold out of Biolase, Inc. (BIOL) in Q1 2022, closing a stake of 2 shares — an estimated $2K sold.

Barclays first reported a position in BIOL in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 28 funds tracked by Wall St. Rank hold BIOL as of Q1 2022.

  • Barclays reported no remaining Biolase, Inc. position as of Q1 2022 after selling out during the quarter.
  • Barclays sold 2 Biolase, Inc. shares in Q1 2022, an estimated $2K.
  • Barclays first reported a position in Biolase, Inc. in Q4 2021 and held it in 1 quarter.
  • Barclays's Biolase, Inc. position peaked at $2K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2022.

Based on Barclays's 13F filing for Q1 2022, filed 16 May 2022.